Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

Morgan Stanley analyst Maxwell Skor has maintained their neutral stance on RPTX stock, giving a Hold rating yesterday.Pick the best stocks and ...

Northwest Bio is near 5-year lows with DCVax vaccine in review. Mixed opinions on trial, but potential remains. Cash issues ...

Using OncoCast-MPM, a ML tool developed at Memorial Sloan Kettering, they generated three models to predict progression-free survival (PFS) with CDK4/6 inhibitors: one based on clinicopathological ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00.Pick ...

Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio. The combo helped women with ...

PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...